Helén Tuvesson new CEO of Active Biotech AB from July 1, 2017
June 19 2017 - 8:30AM
PRESS RELEASE
Lund - Active Biotech AB (Nasdaq
Stockholm: ACTI) today announces that the Board has appointed
the company's current CSO Helén Tuvesson as new CEO of Active
Biotech AB. Helén Tuvesson will take up the position on July 1,
2017, replacing Tomas Leanderson, who has been the company's CEO
since 2008.
Helén Tuvesson has a broad experience in drug development after
more than 20 years in the pharmaceutical industry. Helén has held
various senior positions in Active Biotech and since 2011 she has
been responsible for the company's research and
development.
"I am proud and glad that in Helén Tuvesson we have an internal
candidate who can take responsibility as CEO, ensuring continuity
and a controlled handover. Helén has been instrumental in the
structural changes made in the company during 2016/2017 and has a
solid industry experience. I am convinced that she has the
qualities required to shape the company's future strategy and
maximize its opportunities," says Mats Arnhög, Chairman of the
Board.
"I would also like to thank Tomas Leanderson for his significant
contribution to the company's business for a long period. Tomas
Leanderson will be at the company's disposal during a transitional
period," said Mats Arnhög.
"I am very happy and at the same time humbled for the confidence to
lead Active Biotech further. I am well acquainted with the
company's projects and its potential and look forward to developing
the portfolio further and creating value for the company," says
Helén Tuvesson.
Lund June 19, 2017
Active Biotech AB (publ)
For further information, please
contact:
Mats Arnhög
Chairman of the Board
Tel +46 8 54503770
Mobil: +46 705 915096
Active Biotech AB (publ)
(Nasdaq Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/ inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties, is in Phase 2 development for the treatment of primary
progressive multiple sclerosis and Huntington's disease. Anyara,
cancer immunotherapy, previously in clinical Phase 1-2/3
development in patients with pancreatic-, lung- or renal cancer.
Furthermore, commercial activities are conducted for the
tasquinimod, paquinimod and SILC projects. Please visit
www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
This information is information
that Active Biotech AB is obliged to make public pursuant to the EU
Market Abuse Regulation. This information was submitted for
publication, through the agency of the contact person set out
above, at 15.30 a.m. CET
on June 19, 2017.
Helén Tuvesson new CEO of Active
Biotech AB from July 1, 2017
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Oct 2023 to Oct 2024